FCC Moves to Ban Imports of Foreign Military-Grade Drones Over Security Risks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Lebanon Lawyers Seek Probe Into Banker Over Alleged Netanyahu Dinner in Washington 
Airbus Joins Air India A320 Altitude Drop Probe 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
ADNOC Gas Targets Up to $4B Profit in 2026 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Trump Election Order Blocked Again as Appeals Court Rejects Mail-In Voting Push in 23 States 
Juan Orlando Hernandez Seeks Dismissal of Honduras Charges After Trump Pardon 
25 Democratic-Led States Sue Trump Administration Over New Global Tariffs 
UnitedHealth Group (NYSE: UNH) is under investigation by the U.S. Department of Justice (DOJ) for potential criminal fraud related to its Medicare Advantage business, according to a report by the Wall Street Journal. The healthcare giant’s stock dropped 6.5% in after-hours trading, hitting a near five-year low amid the growing legal scrutiny.
The DOJ’s healthcare-fraud unit has reportedly been probing UnitedHealth since at least mid-2023. While the exact details of the criminal allegations remain unclear, the investigation focuses on whether the company engaged in fraudulent billing or reporting practices in its Medicare operations. This latest development adds to a series of legal challenges facing the insurer.
In addition to the criminal probe, UnitedHealth is also facing a civil investigation tied to Medicare billing practices and separate concerns over potential antitrust violations. The company’s business model, which heavily relies on federal healthcare programs, may come under further pressure as lawmakers consider cost-cutting measures, including efforts to reduce Medicare drug prices.
The mounting scrutiny has triggered leadership changes within the company. Earlier this week, UnitedHealth abruptly replaced CEO Andrew Witty with former CEO and current Chairman Stephen Hemsley. The leadership shakeup comes as the company’s stock has seen a sharp decline in 2025, reflecting investor concerns over its legal exposure and the potential for regulatory reforms.
The DOJ investigation could have significant implications not just for UnitedHealth, but for the broader Medicare Advantage sector, which has faced increased oversight in recent years. As more details emerge, analysts and investors will be closely watching for signs of financial or operational fallout.
